Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9326 USD | +3.05% | -3.24% | -32.45% |
May. 29 | Bluebird bio, Inc. Announces Executive Changes, Effective from June 10, 2024 | CI |
May. 29 | Bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.66% | 174M | C | ||
+18.06% | 125B | B+ | ||
+13.29% | 108B | B+ | ||
-7.26% | 24.21B | B+ | ||
+1.92% | 22.78B | B | ||
-10.79% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.25% | 16.37B | B | ||
+0.73% | 13.58B | C+ | ||
+26.41% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BLUE Stock
- Ratings bluebird bio, Inc.